New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
10:00 EDTPBR, VRTX, KRC, GRMN, BMY, STRA, JNJ, IQNT, HES, VNO, NKTR, JCP, CATOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Caterpillar (CAT) downgraded to Neutral from Overweight at JPMorgan... Garmin (GRMN) downgraded to Sell from Neutral at Goldman... Inteliquent (IQNT) downgraded to Underweight from Equal Weight at Morgan Stanley... J.C. Penney (JCP) downgraded to Underperform from Neutral at Credit Suisse... Johnson & Johnson (JNJ) downgraded to Hold from Buy at Jefferies... Kilroy Realty (KRC) downgraded to Neutral from Buy at BofA/Merrill... Nektar (NKTR) downgraded to Hold from Buy at Jefferies... Strayer Education (STRA) downgraded to Neutral from Overweight at JPMorgan... Vertex (VRTX) downgraded to Neutral from Outperform at Credit Suisse... Vornado (VNO) downgraded to Neutral from Buy at BofA/Merrill... Bristol-Meyers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Petrobras (PBR) downgraded to Neutral from Buy at BofA/Merrill... Hess Corp. (HES) downgraded to Market Perform from Outperform at Howard Weil.
News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 29, 2015
16:19 EDTBMYOn The Fly: Top stock stories for Friday
Stocks on Wall Street began the final trading day of May with slight losses. The averages began to pick up downside momentum after revised GDP numbers confirmed expectations that the economy shrank in the first quarter of the year. The Wall Street adage of “sell in May, then go away” appeared to be taking hold as the S&P broke a support level and took the other averages with it. Investors are now concerned about a June swoon, as it is historically one of the worst performing months of the year. ECONOMIC EVENTS: In the U.S., the second estimate of gross domestic product showed it shrank at a 0.7% seasonally adjusted annual rate in the first quarter. This was down from the previous estimate that output grew 0.2% from January through March, but better than the revision to a 1% decline that had been forecast by analysts. The Chicago PMI unexpectedly dropped 6.1 points to 46.2 in May, versus expectations for it to have risen to a reading of 53. The University of Michigan's consumer sentiment reading came in with a 90.7 reading for the final May print, which was up from the preliminary 88.6 reading for the month but down from April's 95.9 figure. COMPANY NEWS: Shares of Humana (HUM) jumped $36.24, or 20.31%, to $214.65 after The Wall Street Journal said the company has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of takeover interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders for Humana. Bloomberg then said Humana's sale exploration came after Cigna made a takeover approach. Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. MAJOR MOVERS: Among the notable gainers was Heron Therapeutics (HRTX), which gained $7.41, or 60%, to $19.76 after the company reported positive top-line data from a Phase 3 marketing study looking at Sustol as part of a 3-drug regimen for the prevention of delayed-onset chemotherapy-induced nausea and vomiting following administration of highly emetogenic chemotherapy agents. Also higher was Altera (ALTR), which advanced $1.88, or 4%, to $48.85 after reports from The New York Post and Financial Times claimed the company is near a deal to be acquired by chipmaking giant Intel (INTC) for up to $54 per share. Reuters, meanwhile, revised its prior report to indicate the potential price of the deal could be close to $16B. Among the noteworthy losers was Abercrombie & Fitch (ANF), which fell $1.63, or 7.38%, to $20.47 after Janney Capital downgraded the stock to Sell from Hold and warned the company's comparative sales may continue to drop year-over-year as it changes nearly every aspect of its business. Also lower were shares of Bristol-Myers Squibb (BMY), which dropped $4.55, or 6.58%, to $64.60 after the company reported data from a Phase III study evaluating Opdivo in previously-treated patients with advanced, non-squamous non-small cell lung cancer. Biotech analyst Mark Schoenebaum reportedly said Bristol-Myers' data from its Checkmate 057 study opens the door for lung cancer competition from Merck (MRK) and Roche (RHHBY), according to TheStreet's Adam Feuerstein. INDEXES: The Dow dropped 115.44, or 0.64%, to 18,010.68, the Nasdaq lost 27.95, or 0.55%, to 5,070.03, and the S&P 500 fell 13.40, or 0.63%, to 0.63.
14:58 EDTBMYBristol-Myers Opdivo data opens door for competition, Schoenebaum says
Subscribe for More Information
14:49 EDTBMYBristol-Myers tumbles in late afternoon trading
Subscribe for More Information
14:27 EDTBMYBristol-Myers down 4.5% after reporting on Opdivo trials
Subscribe for More Information
14:06 EDTBMYBristol says Opdivo demonstrates anti-tumor activity in hepatocellular carcinoma
Subscribe for More Information
14:04 EDTBMYBristol-Myers says Opdivo demonstrates superior OS versus standard of care
Bristol-Myers Squibb announced that Opdivo is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care, or docetaxel, in an open-label, randomized Phase III study evaluating previously-treated patients with advanced, non-squamous non-small cell lung cancer, or NSCLC. A 27% reduction in the risk of progression or death – the primary study endpoint – was reported for Opdivo versus docetaxel based upon a hazard ratio of 0.73. Opdivo was associated with a doubling of overall median survival across the continuum of PD-L1 expression, starting at 1% level of expression, in the trial. The safety profile of Opdivo in CheckMate -057 was favorable versus docetaxel with grade 3–5 treatment-related adverse events reported in 10% of patients who were treated with Opdivo versus 54% in the docetaxel arm. These data will be featured today, May 29, during the 51st Annual Meeting of the American Society of Clinical Oncology press briefing and presented during a clinical science symposium on Saturday, May 30, the company noted.
12:37 EDTVRTXStocks with call strike movement; VRTX GNW
Subscribe for More Information
10:37 EDTGRMNGarmin prevails in Silver State patent lawsuit
Subscribe for More Information
May 28, 2015
15:11 EDTBMYBristol-Myers to hold a conference call
Subscribe for More Information
12:31 EDTPBRStocks with call strike movement; PBR FB
Petrobras (PBR) October 10 call option implied volatility increased 2% to 52, Facebook (FB) September 90 call option implied volatility increased 2% to 26 according to IVolatility.
11:22 EDTBMYCatalyst Pharmaceutical names Richard Daly as interim Chief Commercial Officer
Subscribe for More Information
11:15 EDTNKTROptions with increasing implied volatility
Subscribe for More Information
09:28 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
09:00 EDTVRTXPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
08:04 EDTJNJCardinal Health confirms binding offer to acquire Cordis accepted from JNJ
Subscribe for More Information
08:02 EDTJNJJohnson & Johnson accepts binding offer from Cardinal Health to acquire Cordis
Subscribe for More Information
May 27, 2015
13:58 EDTCATExxon Mobil announces Doug Oberhelman elected to board
Exxon Mobil (XOM) announced that its shareholders have elected Doug Oberhelman to its board of directors. Oberhelman is chairman of the board of directors and CEO of Caterpillar (CAT). With the election of Oberhelman, the ExxonMobil board stands at 12 directors, 11 of whom are non-employee directors. Oberhelman was named CEO and chairman of Caterpillar’s board in 2010. Prior to that, he served as group president of various divisions within Caterpillar from 2002 to 2010, and was elected a Caterpillar vice president and CFO in 1995.
13:28 EDTJNJFBI investigating Johnson & Johnson over discontinued surgical tool, WSJ says
The FBI is investigating Johnson & Johnson over whether it knew about the potential hazards of a surgical device known as a laparoscopic power morcellator before the device was pulled from the market in 2014, reports The Wall Street Journal, citing three people with knowledge of the matter. The Journal notes that the U.S. FDA recommended a "black box" warning for the device in November, stating that it should not be used on the "vast majority" of women because morcellators can spread malignant cancer and worsen patient outcomes. Reference Link
13:10 EDTJNJJ&J being probed by FBI over discontinued surgical device, DJ reports
Subscribe for More Information
08:03 EDTHESHarris CapRock selected by Hess Corp. for systems integration contract
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use